AGP Picks
View all

Reblozyl market growth to be driven by MDS cases and transfusion-sparing care

Nov. 11, 2026
Reblozyl market growth to be driven by MDS cases and transfusion-sparing care
By AI, Created 16:30 UTC, Nov 11, 2026, AGP -

The Business Research Company says the global Reblozyl market is entering a new growth phase through 2026, fueled by rising myelodysplastic syndrome cases, higher healthcare spending and demand for therapies that reduce blood transfusions. North America led the market in 2025, while Asia-Pacific is projected to grow fastest.

Why it matters: - The Reblozyl market is tied to rising demand for anemia treatments that can reduce dependence on blood transfusions. - Growth in myelodysplastic syndromes and beta-thalassemia is expanding the patient base for luspatercept. - The market outlook points to broader use of biologics and more personalized hematology care.

What happened: - The Business Research Company released its Reblozyl Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 11, 2026. - The report says the global Reblozyl market is entering a period of notable change through 2026. - Reblozyl, or luspatercept, is an injectable medicine used to treat anemia caused by beta-thalassemia and myelodysplastic syndromes. - The drug works by stimulating red blood cell production in the bone marrow and reducing transfusion needs.

The details: - Historical market growth has been supported by higher prevalence of beta-thalassemia and MDS, heavy use of blood transfusions, clinical validation of luspatercept, more specialty hematology centers and regulatory approvals for anemia treatments. - Future growth is expected to come from demand for transfusion-sparing therapies, wider biologics adoption, longer-term anemia management, more rare-disease investment and advances in bone marrow-targeted therapies. - Expected trends include broader use of erythroid maturation agents, wider adoption of targeted anemia therapies, more injectable biologics, lower transfusion dependency and more personalized hematology care. - The report identifies rising MDS incidence as a major demand driver. - The American Cancer Society estimated 10,000 to 15,000 new MDS cases a year in the U.S. in November 2024. - Higher healthcare spending is also supporting market expansion by improving access to treatments such as Reblozyl. - The UK Office for National Statistics reported a 5.6% nominal rise in total healthcare expenditure from 2022 to 2023, compared with 0.9% growth in 2022. - The UK Office for National Statistics also said real-term spending on long-term health and social care rose 2.8% in 2022. - In 2025, North America held the largest share of the Reblozyl market. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report’s new additions include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - More information is available in the company's announcement.

Between the lines: - The report frames Reblozyl as part of a broader shift toward therapies that manage chronic blood disorders with fewer transfusions. - Regional leadership suggests the market is already established in North America, but faster growth may come from expanding access and diagnosis in Asia-Pacific. - The emphasis on rare disease investment and biologics points to a market shaped by specialty care rather than mass-market prescribing.

What's next: - The report expects the market to keep evolving through 2035 as hematology care shifts toward targeted and transfusion-sparing treatment models. - Growth will likely depend on continued adoption of biologic therapies, deeper specialty care infrastructure and broader treatment access in high-growth regions. - The Business Research Company is positioning the 2026 edition with forecasting tools and updated analysis for market tracking.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Africa News Guide

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Africa News Guide

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.